• Corporate
• Markets
• Info-Tech
• Marketing
• Money & Banking
• Agri-Biz & Commodities
• Industry & Economy
• Logistics
• Government
• Opinion
• Variety
• Columns
• States
• Web Extras
• Index

• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• Smartbuy

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

• Rates

• Ports

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Subscription

• Business Line

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

MUMBAI: Drug maker Aurobindo Pharma on Monday said it has received tentative approval from US Food and Drug Administration (USFDA) to manufacture and market Abacavir Sulfate and Lamivudine tablets, used in the treatment of HIV (human immunodeficiency vir us).

The tablets are the generic equivalent of Epizcom tablets of Smithkline Beecham corporation and falls under the anti-retroviral segment, the company said in a filling to the Bombay Stock Exchange.

Aurobindo Pharma would manufacture and market Abacavir Sulfate/ Lamivudine tablets in the strengths of 600 mg and 300 mg, the filing said.

The products have been reviewed under the President's emergency plan for AIDS relief. This is Aurobindo 76th abbreviated new drug application approval from US FDA.

Shares of the company were trading at Rs 320, up 1.25 per cent in afternoon trade on the BSE. - PTI

Prev: Rupee recovers sharply
Next: Essential drugs become scarce in India, Africa

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line